Regenxbio (RGNX) EBITDA (2014 - 2025)

Regenxbio's EBITDA history runs 12 years deep, the most recent figure standing at -$67.2 million for Q4 2025.

• In Q4 2025, EBITDA fell 30.85% year-over-year to -$67.2 million; the TTM figure through Dec 2025 stood at -$193.8 million (up 13.24% YoY), while the FY2025 annual figure was -$193.8 million, up 13.24% from the prior year.
• EBITDA was -$67.2 million for Q4 2025 at Regenxbio, down from -$61.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $292.7 million in Q4 2021 to a low of -$86.1 million in Q1 2022.
• Historically, EBITDA has averaged -$41.9 million across 5 years, with a median of -$59.5 million in 2023.
• Biggest YoY gain for EBITDA was 724.66% in 2021; the steepest drop was 803.7% in 2021.
• A 5-year view of EBITDA shows it stood at $292.7 million in 2021, then slumped by 119.5% to -$57.1 million in 2022, then dropped by 4.95% to -$59.9 million in 2023, then grew by 14.29% to -$51.3 million in 2024, then tumbled by 30.85% to -$67.2 million in 2025.
• The last three EBITDA figures came in at -$67.2 million (Q4 2025), -$61.8 million (Q3 2025), and -$70.9 million (Q2 2025), per Business Quant data.